Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2007

View Archived Issues

Trial results support further investigation of sunitinib in non-small cell lung cancer

Clinical benefit seen with nimotuzumab in non-small cell lung cancer

Degarelix suppresses PSA, testosterone in prostate cancer patients

Sleep maintenance promoting effects of the 5-HT2A receptor antagonist eplivanserin shown in rats

Single-agent talactoferrin improves survival in refractory non-small cell lung cancer

Preclinical characterization of ARH-460-16-2, a novel anti-CD44 MAb

Telmisartan exerts potent PPAR-gamma-mediated antiproliferative activity against PC cells

Inhibition of calcineurin activity using tacrolimus restores memory in a mouse model of AD

Zelos reports positive results of phase I and II trials of Ostabolin-C

Studies reveal increased bone formation with anti-sclerostin antibody

Topical amitriptyline ineffective in treating neuropathic pain

Chelsea reports plans for phase III trials of droxidopa for NOH

Ariad begins phase III trial of deforolimus for metastatic soft-tissue and bone sarcomas

Positive results for DOV Pharmaceutical's phase Ib trial of DOV-21947

Encysive will conduct additional phase III study of Thelin in PAH

Cell Therapeutics begins FDA-approved, phase III advanced NSCLC trial in women

Inflazyme and Biolipox to enter asset purchase agreement

Lundbeck in-licenses Circadin from Neurim

Phase I clinical trial approved for transdermal oxycodone

EMEA grants orphan drug designation to HDAC inhibitor MGCD-0103

Allos completes interim analyses of pivotal phase II trial of PDX for PTCL

Array BioPharma and Celgene sign cancer and inflammation therapeutics agreement

Update on Progen's development of PI-88 for cancer

Schering-Plough begins phase I trial of PS-948115 for respiratory disease

AstraZeneca acquires North American rights to Verus' asthma development programs

In vivo Gram-positive antibacterial activity of novel oxazolidinone compounds

Biodel's two ongoing pivotal phase III trials of VIAject to include European sites

Recent patents divulge novel analgesic agents

Recent patents disclose new anxiolytic, antidepressive and antipsychotic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...